Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Interhemispheric anatomical disconnection in disorders of consciousness patients.

Ferraro S, Nigri A, Nava S, Rosazza C, Sattin D, Sebastiano Rossi D, Porcu L, Bruzzone MG, Marotta G, Benti R, Redolfi A, Leonardi M, D'Incerti L.

J Neurotrauma. 2018 Dec 6. doi: 10.1089/neu.2018.5820. [Epub ahead of print]

PMID:
30520674
2.

Assessment of proportional hazard assumption in aggregate data: a systematic review on statistical methodology in clinical trials using time-to-event endpoint.

Rulli E, Ghilotti F, Biagioli E, Porcu L, Marabese M, D'Incalci M, Bellocco R, Torri V.

Br J Cancer. 2018 Dec;119(12):1456-1463. doi: 10.1038/s41416-018-0302-8. Epub 2018 Nov 13.

PMID:
30420618
3.

Eribulin in the treatment of advanced breast cancer: real-world scenario from 39 Italian centers - ESEMPiO study.

Barni S, Livraghi L, Morritti M, Vici P, Michelotti A, Cinieri S, Fontanella C, Porcu L, Del Mastro L, Puglisi F; ESEMPiO Study Group.

Future Oncol. 2018 Nov 9. doi: 10.2217/fon-2018-0324. [Epub ahead of print]

PMID:
30411979
4.

n-3 Docosapentaenoic acid-derived protectin D1 promotes resolution of neuroinflammation and arrests epileptogenesis.

Frigerio F, Pasqualini G, Craparotta I, Marchini S, van Vliet EA, Foerch P, Vandenplas C, Leclercq K, Aronica E, Porcu L, Pistorius K, Colas RA, Hansen TV, Perretti M, Kaminski RM, Dalli J, Vezzani A.

Brain. 2018 Nov 1;141(11):3130-3143. doi: 10.1093/brain/awy247.

5.

Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade.

Russo GL, Moro M, Sommariva M, Cancila V, Boeri M, Centonze G, Ferro S, Ganzinelli M, Gasparini P, Huber V, Milione M, Porcu L, Proto C, Pruneri G, Signorelli D, Sangaletti S, Sfondrini L, Storti C, Tassi E, Bardelli A, Marsoni S, Torri V, Tripodo C, Colombo MP, Anichini A, Rivoltini L, Balsari A, Sozzi G, Garassino MC.

Clin Cancer Res. 2018 Sep 11. doi: 10.1158/1078-0432.CCR-18-1390. [Epub ahead of print]

PMID:
30206165
6.

Soluble stroma-related biomarkers of pancreatic cancer.

Resovi A, Bani MR, Porcu L, Anastasia A, Minoli L, Allavena P, Cappello P, Novelli F, Scarpa A, Morandi E, Falanga A, Torri V, Taraboletti G, Belotti D, Giavazzi R.

EMBO Mol Med. 2018 Aug;10(8). pii: e8741. doi: 10.15252/emmm.201708741.

7.

Antiepileptic treatment and survival in newly diagnosed glioblastoma patients: Retrospective multicentre study in 285 Italian patients.

Rigamonti A, Imbesi F, Silvani A, Gaviani P, Agostoni E, Porcu L, De Simone I, Torri V, Salmaggi A.

J Neurol Sci. 2018 Jul 15;390:14-19. doi: 10.1016/j.jns.2018.04.004. Epub 2018 Apr 5.

PMID:
29801876
8.

Implant success and safety of left atrial appendage occlusion in end stage renal disease patients: Peri-procedural outcomes from an Italian dialysis population.

Genovesi S, Slaviero G, Porcu L, Casu G, Bertoli S, Sagone A, Pieruzzi F, Rovaris G, Buskermolen M, Danna P, Montoli A, Oreglia J, Contaldo G, Mazzone P.

Int J Cardiol. 2018 Jul 1;262:38-42. doi: 10.1016/j.ijcard.2018.03.083.

PMID:
29706393
9.

Neoadjuvant Chemotherapy Exerts Selection Pressure Towards Luminal Phenotype Breast Cancer.

Galli G, Bregni G, Cavalieri S, Porcu L, Baili P, Hade A, Di Salvo F, Sant M, Agresti R, Gennaro M, Folli S, De Santis MC, Paolini B, Carcangiu ML, de Braud F, Di Cosimo S.

Breast Care (Basel). 2017 Dec;12(6):391-394. doi: 10.1159/000479582. Epub 2017 Dec 12.

10.

Inhibition of monoacylglycerol lipase terminates diazepam-resistant status epilepticus in mice and its effects are potentiated by a ketogenic diet.

Terrone G, Pauletti A, Salamone A, Rizzi M, Villa BR, Porcu L, Sheehan MJ, Guilmette E, Butler CR, Piro JR, Samad TA, Vezzani A.

Epilepsia. 2018 Jan;59(1):79-91. doi: 10.1111/epi.13950. Epub 2017 Nov 24.

PMID:
29171003
11.

Autologous fat tissue grafting improves pulmonary healing after laser metastasectomy.

Furia S, Cadenelli P, Andriani F, Scanagatta P, Duranti L, Spano A, Galeone C, Porcu L, Pastorino U.

Eur J Surg Oncol. 2017 Dec;43(12):2315-2323. doi: 10.1016/j.ejso.2017.09.020. Epub 2017 Oct 16.

PMID:
29111365
12.

The Prison of Shame: Finding a Passage Through Dreams.

Porcu L.

Psychoanal Rev. 2017 Oct;104(5):595-628. doi: 10.1521/prev.2017.104.5.595.

PMID:
29022847
13.

Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study).

Ricotta R, Verrioli A, Ghezzi S, Porcu L, Grothey A, Falcone A, Van Cutsem E, Argilés G, Adenis A, Ychou M, Barone C, Bouché O, Peeters M, Humblet Y, Mineur L, Sobrero AF, Hubbard JM, Cremolini C, Prenen H, Tabernero J, Jarraya H, Mazard T, Deguelte-Lardiere S, Papadimitriou K, Van den Eynde M, Pastorino A, Redaelli D, Bencardino K, Funaioli C, Amatu A, Carlo-Stella G, Torri V, Sartore-Bianchi A, Vanzulli A, Siena S.

ESMO Open. 2017 Feb 13;1(6):e000111. doi: 10.1136/esmoopen-2016-000111. eCollection 2016.

14.

Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?

Grassi P, Verzoni E, Ratta R, Porcu L, Prisciandaro M, Mennitto A, Calareso G, de Braud F, Procopio G.

Drugs R D. 2017 Sep;17(3):461-467. doi: 10.1007/s40268-017-0203-y.

15.

Ascites interferes with the activity of lurbinectedin and trabectedin: Potential role of their binding to alpha 1-acid glycoprotein.

Erba E, Romano M, Gobbi M, Zucchetti M, Ferrari M, Matteo C, Panini N, Colmegna B, Caratti G, Porcu L, Fruscio R, Perlangeli MV, Mezzanzanica D, Lorusso D, Raspagliesi F, D'Incalci M.

Biochem Pharmacol. 2017 Nov 15;144:52-62. doi: 10.1016/j.bcp.2017.08.001. Epub 2017 Aug 4.

PMID:
28782526
16.

Molecular isoforms of high-mobility group box 1 are mechanistic biomarkers for epilepsy.

Walker LE, Frigerio F, Ravizza T, Ricci E, Tse K, Jenkins RE, Sills GJ, Jorgensen A, Porcu L, Thippeswamy T, Alapirtti T, Peltola J, Brodie MJ, Park BK, Marson AG, Antoine DJ, Vezzani A, Pirmohamed M.

J Clin Invest. 2017 Jun 1;127(6):2118-2132. doi: 10.1172/JCI92001. Epub 2017 May 15.

17.

Pharmacodynamic effects in the cerebrospinal fluid of rats after intravenous administration of different asparaginase formulations.

Ballerini A, Moro F, Nerini IF, Marzo CM, Di Clemente A, Ferrari M, D'Incalci M, Biondi A, Colombini A, Conter V, Porcu L, Cervo L, Rizzari C, Zucchetti M.

Cancer Chemother Pharmacol. 2017 Jun;79(6):1267-1271. doi: 10.1007/s00280-017-3307-8. Epub 2017 Apr 19.

PMID:
28424964
18.

Sudden Death in End Stage Renal Disease: Comparing Hemodialysis versus Peritoneal Dialysis.

Genovesi S, Porcu L, Luise MC, Riva H, Nava E, Contaldo G, Stella A, Pozzi C, Ondei P, Minoretti C, Gallieni M, Pontoriero G, Conte F, Torri V, Bertoli S, Vincenti A.

Blood Purif. 2017;44(1):77-88. doi: 10.1159/000464347. Epub 2017 Apr 1.

19.

Efficacy and safety of eribulin in taxane-refractory patients in the 'real world'.

Lorusso V, Cinieri S, Latorre A, Porcu L, Del Mastro L, Puglisi F, Barni S.

Future Oncol. 2017 May;13(11):971-978. doi: 10.2217/fon-2016-0530. Epub 2017 Feb 24.

PMID:
28326833
20.

Outcome of Patients with Renal Cell Carcinoma and Multiple Glandular Metastases Treated with Targeted Agents.

Grassi P, Doucet L, Giglione P, Grünwald V, Melichar B, Galli L, De Giorgi U, Sabbatini R, Ortega C, Santoni M, Bamias A, Verzoni E, Derosa L, Studentova H, Porcu L, De Braud F, Porta C, Procopio G.

Oncology. 2017;92(5):269-275. doi: 10.1159/000455970. Epub 2017 Feb 17.

PMID:
28208153
21.

Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms.

Romano M, Della Porta MG, Gallì A, Panini N, Licandro SA, Bello E, Craparotta I, Rosti V, Bonetti E, Tancredi R, Rossi M, Mannarino L, Marchini S, Porcu L, Galmarini CM, Zambelli A, Zecca M, Locatelli F, Cazzola M, Biondi A, Rambaldi A, Allavena P, Erba E, D'Incalci M.

Br J Cancer. 2017 Jan;116(3):335-343. doi: 10.1038/bjc.2016.424. Epub 2017 Jan 10.

22.

Complete remission in metastatic breast cancer: expecting the unexpected-results of a cross-sectional study.

Galli G, Tessari A, Porcu L, Bregni G, Paolini B, Carcangiu ML, Gennaro M, De Santis MC, Lozza L, de Braud F, Di Cosimo S.

Breast Cancer. 2017 Jul;24(4):635-641. doi: 10.1007/s12282-017-0751-6. Epub 2017 Jan 5.

PMID:
28058615
23.

Efficacy and safety of vinorelbine-capecitabine oral metronomic combination in elderly metastatic breast cancer patients: VICTOR-1 study.

Cazzaniga ME, Torri V, Riva F, Porcu L, Cicchiello F, Capici S, Cortinovis D, Digiacomo N, Bidoli P.

Tumori. 2017 Jan 21;103(1):e4-e8. doi: 10.5301/tj.5000543.

PMID:
27647223
24.

Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort study.

Verzoni E, De Giorgi U, Derosa L, Caffo O, Boccardo F, Facchini G, Porcu L, De Vincenzo F, Zaniboni A, Chiuri VE, Fratino L, Santini D, Adamo V, De Vivo R, Dinota A, Messina C, Ricotta R, Caserta C, Scavelli C, Susi M, Tartarone A, Surace G, Mosca A, Bruno M, Barni S, Grassi P, Procopio G.

Oncotarget. 2016 Jun 28;7(26):40085-40094. doi: 10.18632/oncotarget.9485.

25.

Efficacy and Safety of Bevacizumab Combined With Fluoropyrimidine Monotherapy for Unfit or Older Patients With Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.

Pinto C, Antonuzzo L, Porcu L, Aprile G, Maiello E, Masi G, Petrelli F, Scartozzi M, Torri V, Barni S.

Clin Colorectal Cancer. 2017 Jun;16(2):e61-e72. doi: 10.1016/j.clcc.2016.08.006. Epub 2016 Aug 31. Review.

26.

The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations.

Novello S, Pinto C, Torri V, Porcu L, Di Maio M, Tiseo M, Ceresoli G, Magnani C, Silvestri S, Veltri A, Papotti M, Rossi G, Ricardi U, Trodella L, Rea F, Facciolo F, Granieri A, Zagonel V, Scagliotti G.

Crit Rev Oncol Hematol. 2016 Aug;104:9-20. doi: 10.1016/j.critrevonc.2016.05.004. Epub 2016 May 13.

PMID:
27286698
27.

Cognitive deficits and brain myo-Inositol are early biomarkers of epileptogenesis in a rat model of epilepsy.

Pascente R, Frigerio F, Rizzi M, Porcu L, Boido M, Davids J, Zaben M, Tolomeo D, Filibian M, Gray WP, Vezzani A, Ravizza T.

Neurobiol Dis. 2016 Sep;93:146-55. doi: 10.1016/j.nbd.2016.05.001. Epub 2016 May 10.

PMID:
27173096
28.

Non-clinical factors influencing pain intensity in cancer patients: Socio-cultural-economic status, awareness of disease and the relation with the oncologist.

Corli O, Martoni AA, Porcu L, Roberto A, Pinto C, Torri V, Guglieri I, Zagonel V; EPIDEMIOLOGY STUDY OF PAIN IN ONCOLOGY (ESOPO) GROUP.

Eur J Intern Med. 2016 Sep;33:e18-9. doi: 10.1016/j.ejim.2016.04.019. Epub 2016 May 5. No abstract available.

PMID:
27155804
29.

Sacral Chordoma: Long-term Outcome of a Large Series of Patients Surgically Treated at Two Reference Centers.

Radaelli S, Stacchiotti S, Ruggieri P, Donati D, Casali PG, Palmerini E, Collini P, Gambarotti M, Porcu L, Boriani S, Gronchi A, Picci P.

Spine (Phila Pa 1976). 2016 Jun;41(12):1049-57. doi: 10.1097/BRS.0000000000001604.

PMID:
27054448
30.

Multimodal study of default-mode network integrity in disorders of consciousness.

Rosazza C, Andronache A, Sattin D, Bruzzone MG, Marotta G, Nigri A, Ferraro S, Rossi Sebastiano D, Porcu L, Bersano A, Benti R, Leonardi M, D'Incerti L, Minati L; Coma Research Center, Besta Institute.

Ann Neurol. 2016 May;79(5):841-853. doi: 10.1002/ana.24634. Epub 2016 Mar 29.

PMID:
26970235
31.

Patient-derived ovarian cancer xenografts re-growing after a cisplatinum treatment are less responsive to a second drug re-challenge: a new experimental setting to study response to therapy.

Ricci F, Fratelli M, Guffanti F, Porcu L, Spriano F, Dell'Anna T, Fruscio R, Damia G.

Oncotarget. 2017 Jan 31;8(5):7441-7451. doi: 10.18632/oncotarget.7465.

32.

Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma.

Belli C, Piemonti L, D'Incalci M, Zucchetti M, Porcu L, Cappio S, Doglioni C, Allavena P, Ceraulo D, Maggiora P, Dugnani E, Cangi MG, Garassini G, Reni M.

Cancer Chemother Pharmacol. 2016 Mar;77(3):477-84. doi: 10.1007/s00280-015-2932-3. Epub 2015 Dec 14.

PMID:
26666646
33.

In Response.

Billè A, Porcu L.

J Thorac Oncol. 2015 Sep;10(9):e93-e94. doi: 10.1097/JTO.0000000000000614. No abstract available.

34.

Cediranib combined with chemotherapy reduces tumor dissemination and prolongs the survival of mice bearing patient-derived ovarian cancer xenografts with different responsiveness to cisplatin.

Decio A, Cesca M, Bizzaro F, Porcu L, Bettolini R, Ubezio P, Taraboletti G, Belotti D, Giavazzi R.

Clin Exp Metastasis. 2015 Oct;32(7):647-58. doi: 10.1007/s10585-015-9734-1. Epub 2015 Jul 17.

PMID:
26185056
35.

Sites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenib.

Grassi P, Verzoni E, Porcu L, Iacovelli R, de Braud F, Procopio G.

Ther Adv Urol. 2015 Apr;7(2):59-68. doi: 10.1177/1756287215571809.

36.

Mortality, sudden death and indication for cardioverter defibrillator implantation in a dialysis population.

Genovesi S, Porcu L, Luise MC, Riva H, Nava E, Stella A, Pozzi C, Ondei P, Minoretti C, Gallieni M, Pontoriero G, Conte F, Torri V, Vincenti A.

Int J Cardiol. 2015;186:170-7. doi: 10.1016/j.ijcard.2015.03.178. Epub 2015 Mar 17.

PMID:
25819895
37.

Disease progression pattern in metastatic breast cancer patients treated with anti-HER2 therapies.

Serpico D, Porcu L, Tessari A, Gevorgyan A, Bregni G, Galli G, de Braud F, Torri V, Di Cosimo S.

Clin Transl Oncol. 2015 Jul;17(7):530-8. doi: 10.1007/s12094-015-1274-2. Epub 2015 Jan 21.

PMID:
25604128
38.

Oral prevalence and clearance of oncogenic human papilloma virus in a rehabilitation community for substance abusers in Italy: a case of behavioral correction?

Pugliese DB, Bruzzesi G, Montaldo C, Porcu L, Landi M, Mastinu A, Torri V, Licitra L, Locati LD.

J Oral Pathol Med. 2015 Oct;44(9):728-33. doi: 10.1111/jop.12291. Epub 2014 Nov 17.

PMID:
25401955
39.

Efficacy of trastuzumab in unselected patients with HER2-positive metastatic breast cancer: a retrospective analysis.

Collovà E, Ferzi A, Scandurra G, Aurilio G, Torri V, Porcu L, Sanò MV, Taibi E, Foglietta J, Generali D, Andreis D, Dazzani MC, Bramati A, Marcon I, Atzori F, Cinieri S, Tondulli L, Grasso D, Nolè F, Petrella MC, Gori S, La Verde N.

Tumori. 2014 Jul-Aug;100(4):426-31. doi: 10.1700/1636.17902.

PMID:
25296592
40.

Thulium laser versus staplers for anatomic pulmonary resections with incomplete fissures: negative results of a randomized trial.

Scanagatta P, Furia S, Billè A, Duranti L, Girelli L, Tavecchio LD, Leo F, Giovannetti R, Pelosi G, Porcu L, Pastorino U.

Tumori. 2014 May-Jun;100(3):259-64. doi: 10.1700/1578.17196.

PMID:
25076235
41.

Targeted therapies in advanced renal cell carcinoma: the role of metastatic sites as a prognostic factor.

Grassi P, Verzoni E, Porcu L, Testa I, Iacovelli R, Torri V, Braud Fd, Procopio G.

Future Oncol. 2014 Jun;10(8):1361-72. doi: 10.2217/fon.14.69.

PMID:
25052747
42.

Sequential Tyrosine Kinase Inhibitors (TKIs) in metastatic renal cell carcinoma: results from a large cohort of patients.

Biondani P, Verzoni E, Torri V, Porcu L, Grassi P, Testa I, DE Braud F, Procopio G.

Anticancer Res. 2014 May;34(5):2395-8.

PMID:
24778049
43.

Use of adjuvant chemotherapy (CT) and radiotherapy (RT) in incompletely resected (R1) early stage Non-Small Cell Lung Cancer (NSCLC): a European survey conducted by the European Society for Medical Oncology (ESMO) young oncologists committee.

Califano R, Karamouzis MV, Banerjee S, de Azambuja E, Guarneri V, Hutka M, Jordan K, Kamposioras K, Martinelli E, Corral J, Postel-Vinay S, Preusser M, Porcu L, Torri V.

Lung Cancer. 2014 Jul;85(1):74-80. doi: 10.1016/j.lungcan.2014.03.010. Epub 2014 Mar 16.

PMID:
24746176
44.

Does surgery improve survival of patients with malignant pleural mesothelioma?: a multicenter retrospective analysis of 1365 consecutive patients.

Bovolato P, Casadio C, Billè A, Ardissone F, Santambrogio L, Ratto GB, Garofalo G, Bedini AV, Garassino M, Porcu L, Torri V, Pastorino U.

J Thorac Oncol. 2014 Mar;9(3):390-6. doi: 10.1097/JTO.0000000000000064.

45.

Clinical outcome of HER2-positive breast cancer patients after failure on adjuvant trastuzumab: the potential of the time to relapse.

Di Cosimo S, Serpico D, Porcu L, Molino L, Fanetti G, Torri V, de Braud F.

Clin Oncol (R Coll Radiol). 2014 Mar;26(3):174. doi: 10.1016/j.clon.2013.11.028. Epub 2013 Dec 22. No abstract available.

PMID:
24368057
46.

The impact of personalized medicine on survival: comparisons of results in metastatic breast, colorectal and non-small-cell lung cancers.

Rossi A, Torri V, Garassino MC, Porcu L, Galetta D.

Cancer Treat Rev. 2014 May;40(4):485-94. doi: 10.1016/j.ctrv.2013.09.012. Epub 2013 Sep 25. Review.

PMID:
24112813
47.

ALDH enzymatic activity and CD133 positivity and response to chemotherapy in ovarian cancer patients.

Ricci F, Bernasconi S, Porcu L, Erba E, Panini N, Fruscio R, Sina F, Torri V, Broggini M, Damia G.

Am J Cancer Res. 2013 Apr 3;3(2):221-9. Print 2013.

48.

Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104).

Romano M, Frapolli R, Zangarini M, Bello E, Porcu L, Galmarini CM, García-Fernández LF, Cuevas C, Allavena P, Erba E, D'Incalci M.

Int J Cancer. 2013 Nov;133(9):2024-33. doi: 10.1002/ijc.28213. Epub 2013 May 25.

49.

Pure epileptic headache and related manifestations: a video-EEG report and discussion of terminology.

Cianchetti C, Pruna D, Porcu L, Peltz MT, Ledda MG.

Epileptic Disord. 2013 Mar;15(1):84-92. doi: 10.1684/epd.2013.0552.

50.

Prognostic factors for survival in patients with metastatic renal cell carcinoma treated with targeted therapies.

Procopio G, Verzoni E, Iacovelli R, Biasoni D, Testa I, Porcu L, De Braud F.

Br J Cancer. 2012 Oct 9;107(8):1227-32. doi: 10.1038/bjc.2012.327. Epub 2012 Sep 11.

Supplemental Content

Support Center